We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Futura Medical
Eroxon poised for launch in key US marketAvacta
AACR data continue to support confidence in AVA6000Futura Medical
Profitability in sight as partner preps for US launchHUTCHMED
Executing consistently on the road to breakevenRedx Pharma
Voluntary delisting from AIM to go privateArecor Therapeutics
TRx co-development deal centred on oral GLP-1 productAvacta
Successful £31.1m fundraise despite challenging marketsHUTCHMED
FY23 results point to strong financials and fundamentalsRedx Pharma
Ready to ROCK as RXC008 enters the clinicHUTCHMED
Fruquintinib clinical and commercial updates